For Your Patients: What to Know About Breast Cancer HER2 Status — The presence or absence of a specific protein helps guide treatment decisions ...

8 Galdy S, Lamarca A, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?

The study investigates the interaction between the human epidermal growth receptor 2 (HER2) and amygdalin, a compound found in peaches, almonds, and apples. To assess the potential of amygdalin ...

Study reveals new indicators for HER2+ breast cancer response to therapy by Molly Chiu, Baylor College of Medicine edited by Lisa Lock, reviewed by Andrew Zinin Editors' notes ...

The findings highlight HER3-DXd as a potential novel treatment for patients with secondary central nervous system involvement. CHICAGO, May 30, 2025 /PRNewswire/ -- Leading international medical ...

The TUXEDO-3 study aimed to assess whether HER3-DXd could be an effective treatment option for patients with mBC and aNSCLC with active brain metastases, and leptomeningeal disease from solid tumors.

When Merck & Co. | After Merck paid a hefty sum to co-develop and co-commercialize HER3-DXd, the drug has suffered notable setbacks in consecutive years.

5552Background: HER2 and HER3 are critical members of the ERBB receptor family, playing pivotal roles in tumorigenesis across multiple cancers, including ovarian cancer (OC). While their potential as ...

AI could help pathologists identify HER2-low and HER2-ultralow breast cancers with greater accuracy, according to findings scheduled for presentation at ASCO Annual Meeting.In a study of more than ...

HER3 functions through its interaction with other ErbB receptors, particularly HER2, forming potent signaling pairs that drive cell survival, proliferation, and metastasis.

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.